Secondary Logo

Institutional members access full text with Ovid®

The Impact of Parecoxib on Pain Management for Laparoscopic Cholecystectomy

A Meta-analysis of Randomized Controlled Trials

Luo, Zhifang, PhD; Wang, Huarong, PhD; Huang, Dinggui, PhD

Surgical Laparoscopy Endoscopy & Percutaneous Techniques: April 2019 - Volume 29 - Issue 2 - p 69–74
doi: 10.1097/SLE.0000000000000626
Review Articles
Buy

Introduction: The efficacy of parecoxib on pain management for laparoscopic cholecystectomy remains controversial. We conducted a systematic review and meta-analysis to explore the impact of parecoxib on pain management after laparoscopic cholecystectomy.

Materials and Methods: We searched PubMed, EMbase, Web of science, EBSCO, and Cochrane library database results through September 2018 for randomized controlled trials to assess the effect of IV parecoxib versus placebo or noting on pain management after laparoscopic cholecystectomy. This meta-analysis was performed using the random-effect model.

Results: Seven randomized controlled trials were included in the meta-analysis. Overall, compared with control group for laparoscopic cholecystectomy, intravenous parecoxib showed no notable impact on pain scores within 2 hours [mean difference (MD), −0.22; 95% confidence interval (CI), −0.82 to 0.38; P=0.48] and 4 hours (MD, −0.33; 95% CI, −1.04 to 0.38; P=0.36), but showed results of significant decrease in pain scores at 6 hours (MD, −0.82; 95% CI, −1.45 to −0.20; P=0.01), 12 hours (MD, −0.69; 95% CI, −1.23 to −0.15; P=0.01), 24 hours (MD, −0.49; 95% CI, −0.89 to −0.10; P=0.01), and postoperative analgesics need (risk ratio, 0.45; 95% CI, 0.30-0.65; P<0.0001). In addition, no increase in nausea and vomiting is observed after parecoxib use compared with control intervention (risk ratio, 0.89; 95% CI, 0.44-0.76; P=0.76).

Conclusions: Parecoxib can substantially promote postoperative pain relief in patients with laparoscopic cholecystectomy.

ChongQing Traditional Chinese Medicine Hospital, Chongqing, P.R. China

Z.L. and H.W. contributed equally.

The authors declare no conflicts of interest.

Reprints: Dinggui Huang, PhD, No.6, Panxi Road, Seven Branch, Jiangbei District, Chongqing 400021, P.R. China (e-mail: huangdinggui@126.com).

Received October 7, 2018

Accepted November 26, 2018

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.